Jennifer Vieira
Investor Relations
Replay available
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) Q1 2023 earnings conference call, held 2023-02-07. Replay captured from the company's public earnings webcast.

Investor Relations
President and Chief Executive Officer
Chief Financial Officer
Investor (RBC)
Investor (Piper Sandler)
Investor (HC Wainwright & Co.)
Investor (JPMorgan)
Investor (JMP Securities)
Watch the replay and follow the connected company analysis, news, and investor updates for Enanta Pharmaceuticals, Inc..
WEBVTT 00:00:00.009 -- 00:00:05.832 Good afternoon and welcome to Enanta Pharmaceuticals' fiscal first quarter ended December 00:00:05.832 -- 00:00:09.213 31st, 2022 financial results conference call. 00:00:09.213 -- 00:00:12.455 At this time, all participants are in a listen-only mode. 00:00:12.455 -- 00:00:15.977 After the speaker presentation, there'll be a question and answer session. 00:00:15.977 -- 00:00:20.439 To ask a question during the session, you will need to press star 1-1 on your telephone. 00:00:20.439 -- 00:00:24.221 You will then hear an automated message advising your hand is raised. 00:00:24.221 -- 00:00:27.790 To withdraw your question, please press star 1-1 again. 00:00:27.790 -- 00:00:30.070 Please be advised that today's conference is being recorded. 00:00:30.070 -- 00:00:35.511 I would now like to hand the conference over to Jennifer Vieira, Investor Relations. 00:00:35.511 -- 00:00:37.851 Please go ahead. 00:00:39.412 -- 00:00:43.833 Thank you, Operator, and thanks to everyone for joining us this afternoon. 00:00:43.833 -- 00:00:48.994 The news release with our fiscal first quarter 2023 financial results was issued 00:00:48.994 -- 00:00:52.774 this afternoon and is available on our website. 00:00:52.774 -- 00:00:57.861 On the call today are Dr. Jay Lulli, President and Chief Executive Officer, 00:00:57.861 -- 00:01:03.062 Paul Mellett, our chief financial officer, and other members of Enanter's senior 00:01:03.062 -- 00:01:05.363 management team. 00:01:05.363 -- 00:01:09.524 Before we begin with our formal remarks, we want to remind you that we will be making 00:01:09.524 -- 00:01:14.926 forward-looking statements, which may include our plans and expectations with respect 00:01:14.926 -- 00:01:20.147 to our research and development pipeline a...